Cannabis market intelligence
Decision-grade intelligence
for global cannabis.
Cannamonitor turns primary sources, market research and proprietary datasets into structured, analyst-curated intelligence.
120+countries covered1,000+companies tracked40+updated datasets420+sources monitored
Trusted by operators, investors and regulators across 15+ countries
Published intelligence
Research that moves markets.
Data-driven analysis built from the same primary-source intelligence that powers Decide.
Germany · 30 Jul 2026
Germany’s price reset: 52% wiped off pharmacy prices in two years
€10/g before legalisation → €4.65/g by Q2 2026 — a ~52% fall, reconciled across six independent series
Read →
Science · 11 Jun 2026
Cannabinoids come of age: the clinical-trial pipeline behind Vertanical’s Exilby
Nearly 500 active trials; annual starts up 3.5× in five years (from a 1,305-trial database)
Read →
United Kingdom · 14 May 2026
UK medical cannabis market doubles again — and flower loses share
+113% CAGR through 2024; H1 2025 tracking above 15 tonnes on Q2 run-rate
Read →
Reimbursement · 10 Jul 2026
Germany’s six-month gate: 82% of reimbursed cannabis at risk
GKV flower spend €124.74M (+20.8% YoY) — now ~50% of reimbursed spend
Read →
Products · 22 Jul 2026
Inside medical cannabis concentrates: hash and rosin reach the international shelf
UK listed its first medical hash in May 2026; rosin holds a 30–40% per-mg premium over the category average
Read →
Switzerland · 3 Jul 2026
Inside Swiss medical cannabis: maturing beyond oils and pain — but who pays?
Two federal MeCanna datasets (Aug 2022–Jul 2023, Aug 2023–Jul 2025): patient base broadening beyond pain, product mix moving decisively toward flower
Read →
Our analysis is cited in the press — and presented on stage
What we fix
Cannabis data is abundant. Decision-grade cannabis data is not.
Anyone can find a number. Knowing what it counts, what it leaves out and whether it agrees with the three sources that contradict it — that is the work, and that is the product.
What you are working with
What Cannamonitor gives you
✕
Numbers that don’t compareThe same market reported in four currencies, three units and two definitions — nothing reconciles.
→
✓
One schemaEvery figure standardised to one currency basis, one unit and one taxonomy, so numbers compare across jurisdictions and across time.
✕
Figures you cannot act onA growth rate with no base. A total with no definition. A record with no comparison.
→
✓
Decision-grade contextEvery figure ships with its denominator, definition, period and caveat — and the analyst read on what it actually means for the decision.
✕
AI answers you cannot auditA model synthesises contradictory public sources at speed and cites nothing you can check.
→
✓
Primary-source attributionFilings, regulator documents, customs data and court records — traced to origin, with the underlying document one click away.
✕
Data you cannot queryPDFs, screenshots and press releases. Nothing filterable, comparable or exportable.
→
✓
Structured datasets40+ datasets across 120+ countries — filter, compare, chart and export, from 420+ monitored sources.
✕
Nobody owns the judgementAggregators pass through whatever they scrape. When two sources disagree, the error reaches you.
→
✓
Analyst curationNothing enters without human review. Contradictions are reconciled and explained, never averaged away.
Free · every month
The Monthly Intelligence Brief.
A monthly review of the international cannabis markets — regulation, trade, deals and science, with the numbers behind each move. Read by 3,500+ decision-makers.
Subscribe
Unlock the insights trusted by 3,500+ cannabis leaders
Subscribers receive each issue on the day it ships. Everyone else waits a month.
Join 3,500+ cannabis leaders. No spam, unsubscribe in one click.
The platform · Decide
Twelve modules. One connected graph.
Countries and Companies are the spine. Everything else connects back to them — 40+ datasets, 600+ deals, 2,300+ trials, 10,000+ news items. 420+ monitored sources. 120+ countries. One graph.
Countries
The market-entry OS — a full relational profile per market.
- Regulation, demand, supply and competition, per jurisdiction.
- Linked to every company, deal and dataset in that market.
- Size a market or justify a pivot from one page.
| Market | Patients | Imports |
|---|---|---|
| 🇩🇪 Germany | ~900k | 205.2 t |
| 🇬🇧 UK | — | 30 t |
| 🇨🇭 Switzerland | — | 4.1 t |
Companies
The same OS, per operator — 1,000+ profiles.
- Financials, news, deals, trials and licences on one page.
- The value is the integration — everything already joined up.
- Benchmark any operator against its market and peers.
| Operator | Market | Deals |
|---|---|---|
| Vertanical | 🇩🇪 DE | 1 |
| Tilray | 🇨🇦 CA | 12 |
| Somaí | 🇵🇹 PT | 3 |
News
10,000+ items. Vetted, in-platform, past the paywalls.
- Vetted sources only — signal, not noise.
- Analyst summaries so you grasp it fast.
- Never leave the platform to read the story.
BfArMSource document attached
Regulatory
Every rule tracked by liberalisation, momentum and risk.
- Laws, policy, regulators and licences — updated as situations develop.
- Liberalisation momentum and political-risk scoring per market.
- Tied to the country and the companies it affects.
DEUKCHPLAU
Market data
40+ structured datasets. Trade flows, product directories, telemedicine, prevalence, pricing.
- Germany imports & exports, Canada flower exports, UK product directory, telemedicine across 4 markets.
- Filter, chart and export.
- Cross-cuts countries and companies.
Clinical trials
2,300+ trials. Standardised across phases, indications, sponsors.
- Find evidence by condition, substance and population.
- Readouts and status tracked over time.
- Matched to the company and product behind each trial.
THCCBD1:1Other
Science & R&D
The pipeline behind the market. Studies, readouts, investigational products.
- 71 investigational products tracked by indication, phase, mechanism and sponsor — 11 at Phase III or beyond.
- Peer-reviewed studies and readouts, linked to the trials and companies behind each asset.
- Same taxonomy as the trials database — move from evidence to product to company without leaving the graph.
Phase IISource document attached
Earnings
550+ filings. Comparable, not just collected.
- Standardised currency, units and definitions.
- Private-company signals, not only listed names.
- Tracked over time — margins and trajectory.
Q1Q2Q3Q4Q1
Content hub
30+ country briefs updated monthly. Plus insight datapacks and webinar recaps.
- 30+ country briefs, updated monthly with the latest data.
- Every insight datapack and webinar recap — with the primary data behind each figure, linked to its source.
- The full published archive, expanded and source-linked.
MonthlySource document attached
M&A & Funding
600+ deals. Consideration, multiples, investors — normalised.
- Normalised to USD and source-linked.
- Consideration split and multiples where disclosed.
- Each deal connected to buyer, target and market.
| Deal | Value |
|---|---|
| Aphria–Tilray | $3.9bn |
| Cresco–Origin | $1.1bn |
| Trulieve–Harvest | $2.1bn |
Investors
160+ investors. Who’s backing what, and at what price.
- Funds, strategics and lenders behind the deals.
- Linked to their portfolio companies.
- Spot active and emerging backers by market.
FundsStrategicsLendersOther
Analyst datapacks
120+ analyst deep-dives. The “so what”, packaged with the data behind it.
- Topic-level deep-dives built by analysts.
- The data behind every claim, attached.
- New packs added continuously.
Germany 2026Source document attached
Click any module to see what it holds
Testimonials
Trusted where the decisions get made.
Operators, investors, founders and analysts who run their calls on our data.
“The report is amazing. Congrats for being the most loved and hated person in cannabis at the same time.”
“The best reports on the market. The depth, concise insights, data visualisation — all of this make it #1.”
“Cannamonitor is the best source of international cannabis activity out there!”
“The report adds great value to the sector! Many thanks for your dedication and analysis.”
“Cannamonitor lay out a wide range of services that were exactly as requested and beyond. The professionalism in the approach was second only to the quality of commercial leads we generated as a result.”
“The quality of the information received was very specific after an in-depth analysis of the company’s strategy. Most positive was the extensive knowledge in the cannabis industry.”
“We acquired a very high depth of knowledge in a relatively small amount of time. The presentation was detailed and structured with comprehensive and attractive visuals.”
Where to start
Four ways to work with us.
Start free. Move up when the question gets bigger.
Monthly Brief
Free
One email a month. What moved in regulation, markets and science.
- ✓Monthly brief, one month after publication
- ✓Free insight articles
- ✕Same-day access to the brief
- ✕Structured datasets
- ✕Company & country profiles
Essentials
€142/year
Track the whole market. For a single professional staying current.
- ✓Brief on publication day
- ✓Full insight archive
- ✓Curated news & regulatory feed
- ✕Structured datasets & exports
- ✕Company & country profiles
Most popular
Decide
€1,420/year
The full connected graph, every module. For a professional making executive decisions.
- ✓Everything in Essentials
- ✓All 12 connected modules
- ✓40+ structured datasets, filter & export
- ✓Company, country, deal & trial profiles
- ✕Multi-seat, API and bespoke work
Enterprise & advisory
Quoted
Multi-seat access, API, bespoke monitoring and commissioned research.
- ✓Everything in Decide
- ✓Multi-seat & SSO
- ✓API and data delivery
- ✓Tailored taxonomies & alerts
- ✓Commissioned research & advisory
Start with the brief. Decide when you’re ready.
Free, monthly, and read by 3,500+ people who move this market.